Supreme Court directs Centre to draft law curbing unethical pharmaceutical marketing

The Supreme Court of India has instructed the Centre to constitute an expert committee tasked with drafting comprehensive legislation to regulate unethical marketing practices by pharmaceutical companies. The bench issued the directive while considering a petition that detailed widespread instances of improper inducements offered to medical professionals to promote particular drugs.

The petition outlined a range of objectionable practices employed by pharmaceutical firms, including the provision of expensive gifts, sponsorship of foreign trips, and the offering of various other incentives designed to sway doctors towards prescribing specific medications. High-pressure marketing tactics and financial inducements have been identified as significant concerns within the industry, raising questions about the integrity of medical decision-making and patient welfare.

The court's intervention underscores growing judicial concern about the absence of robust regulatory frameworks governing pharmaceutical marketing conduct in India. Currently, the industry operates under guidelines rather than statutory law, which critics argue lacks sufficient enforcement mechanisms to deter unethical behaviour.

The mandated committee is expected to examine existing global best practices and domestic requirements before proposing legislation designed to protect the medical profession's integrity and ensure that prescription decisions are based solely on clinical merit. The development marks a significant step towards establishing stricter oversight of promotional activities within India's pharmaceutical sector.